Business
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
Presentations and panel discussions to provide deeper dives into the clinical outcomes from Insulet’s groundbreaking SECURE-T2D and RADIANT trials Real-world
About this update from Insulet Corporation
[{"type":"text","content":"\n\nPresentations and panel discussions to provide deeper dives into the clinical outcomes from Insulet’s groundbreaking SECURE-T2D and RADIANT trials\n\n\n\nReal-world evidence around glycemic outcomes from more than 23,000 people with type 2 diabetes using Omnipod 5 in the United States will also be shared\n\n\n\nBooth activities include podcasts, hands-on demonstrations led by clinical experts, and immersive experiences, including a comic book featuring a new hero with type 1 diabetes\n\n\n\n ACTON, Mass.--(BUSINESS WIRE)--\nInsulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 85th Scientific Sessions taking place June 20 – 23, 2025 at the McCormick Place Convention Center in Chicago, Illinois.\n\n\n“We are thrilled to share more details that dive deeper into the clinical outcomes from our groundbreaking SECURE-T2D and RADIANT trials, as well as the real-world outcomes we are seeing, especially with type 2 diabetes,” said Dr. Trang Ly, MBBS, FRACP, PhD, Insulet Senior Vice President and Chief Medical Officer. “We are also looking forward to many conversations with healthcare providers about what the outcomes mean, with practical insights on how to optimize therapy.”\n\n\nInsulet shared results of the first large pivotal trial of Automated Insulin Delivery (AID) in type 2 diabetes (SECURE-T2D) at last year’s ADA conference. In March, Insulet presented results of the first randomized controlled trial to assess the direct transition from multiple daily injections (MDI) to AID in adults and children with type 1 diabetes not meeting glycemic targets with injections (RADIANT). Presentations at ADA this week will provide richer insights into both trials and more.\n\n\nConference Activities:\n\n\nDr. Ly will lead a panel discussion, “Setting the Standard with Omnipod 5: Remarkable Results with Unmatched Simplicity,” on Sunday, June 22 from 10:15 – 11:00 AM CT in the conference product theater. She will be joined by Dr. Anders L. Carlson, MD, Associate Executive Director, International Diabetes Center, Director, HealthPartners Diabetes Program, and Associate Professor, University of Minnesota Medical School; Dr. Gregory Forlenza, MD, MS, Associate Profe...